Concord Biotech announced that the US Food and Drug Administration (US FDA) has completed an inspection of its formulation facility located at Unit II–297–298/2p, at. Valthera, Tal. Dholka, Dist. Ahmedabad, Gujarat.

According to the company, the inspection concluded with one minor procedural observation, which it stated is not related to Good Manufacturing Practices (GMP).

Concord Biotech said it will submit a comprehensive response to the observation within the stipulated timeline.

The company did not provide further details on the nature of the procedural observation.